Abstract:In a cohort of patients with extensive‐stage small cell lung cancer undergoing immunotherapy, this study explored the role of radiotherapy and delve into brain metastases subgroup. Brain and thoracic radiotherapy were identified as favorable prognostic factors for survival in those with brain metastases. Moreover, prophylactic cranial irradiation and thoracic radiotherapy delayed intracranial progression in those initially without brain metastases. These findings underscore the pivotal role of local therapies in the management of extensive‐stage small cell lung cancer during the immunotherapy era. Background Extensive‐stage small cell lung cancer (ES‐SCLC) is a notoriously aggressive malignancy frequently associated with brain metastases (BMs), presenting substantial therapeutic challenges. This study delves into the effectiveness of immunotherapy combined with diverse radiotherapy, especially the influence of brain radiotherapy (BRT) on survival outcomes in the immunotherapy era. Methods ES‐SCLC patients treated at Xiangya Hospital and Xiangya Boai Hospital from February 2020 to June 2024 were retrospectively included. The study focused on patients receiving immune checkpoint inhibitors (ICIs). Metrics included overall survival (OS) and progression‐free survival (PFS), employing univariate and multivariate Cox regression models for statistical analysis. Results A total of 393 patients with ES‐SCLC who received ICIs were included in the study. Within the entire cohort, the presence of baseline BMs did not statistically affect OS or PFS. However, thoracic radiotherapy (TRT) was identified as a favorable prognostic factor for both OS and PFS. BRT demonstrated a beneficial effect on OS across both the general cohort and the baseline_BMs subgroup. In patients from the baseline_BMs subgroup who had previously undergone TRT, ICIs plus BRT did not significantly improve OS compared to ICIs alone. Conversely, for patients who had not received prior TRT, adding BRT to ICIs significantly enhanced OS. Among the patients who underwent BRT, 71 received whole brain radiotherapy (WBRT) while 19 opted for stereotactic radiosurgery (SRS). No significant differences in OS and PFS were observed between the SRS and WBRT modalities. The sequence of ICIs relative to BRT was found to influence PFS adversely. Administering BRT before ICIs (RT‐ICI) was associated with worse PFS compared to administering ICIs followed by BRT (ICI‐RT). Additionally, no significant differences in OS and PFS were noted among the three subgroups defined by varying intervals between ICIs and BRT. For patients without baseline BMs, TRT and prophylactic cranial irradiation were associated with delayed onset of brain metastases. Conclusions Our study underscores the importance of optimizing treatment strategies and considering the timing and integration of radiotherapy and immunotherapy to improve outcomes for patients with ES‐SCLC, particularly those at risk of or presenting with BMs.

Does Brain Radiotherapy Improve Survival in Patients with Esophageal Squamous Cell Carcinoma with Brain Metastasis?

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Analyses of Prognostic Factors in Cases of Non-Small Cell Lung Cancer with Multiple Brain Metastases

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

Clinicopathological Features and Prognoses in Patients With Brain Metastases From Small-Cell Esophageal Carcinoma: A Retrospective Analysis of 18 Patients

The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis

Survival benefit of radiotherapy and surgery in lung cancer brain metastases with poor prognosis factors

Analysis of Prognostic Factors in NSCLC Patients with Brain Metastases Diagnosed by Constrast-enhanced MRI After Whole Brain Radiotherapy

[Prognostic predictors for non-small cell lung cancer patients with brain metastasis after radiotherapy.].

Survival and Effective Prognostic Factors in Lung Cancer Patients with Brain Metastases Treated with Whole Brain Radiotherapy

Treatment and survival of patients with small cell lung cancer and brain metastasis

Whole-Brain Radiotherapy Can Improve the Survival of Patients with Multiple Brain Metastases from Non-Small Cell Lung Cancer Treated by Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Effects of Whole-Brain Radiation Therapy and Other Factors on Survival in Patients with Brain Metastases from Lung Cancer

Relationship Between WBRT Total Dose, Intracranial Tumor Control, and Overall Survival in NSCLC Patients with Brain Metastases - a Single-Center Retrospective Analysis

Metastatic Brain Tumors from Small-Cell Esophageal Cancer: Clinical Characteristics and Outcome

The Effects of Brain Radiotherapy Selection on the Survival of Driver Gene-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases

PUB085 Outcomes of Small Cell Lung Cancer Patients with Brain Metastases: Prognostic Factors Based on an Analysis of 225 Cases

Multimodal Therapy is a Better Choice for Patients with Brain Metastasis from Cervical Cancer

[Survival Status of Stage IV Non-Small Cell Lung Cancer Patients after Radiotherapy--a Report of 287 Cases].

Overall Survival after Radiotherapy for Brain Metastases according to ECOG Status—A Prospective Study of 294 NSCLC Patients